

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Xiangzhu Wang	09/03/2008
Suoming Zhang	09/24/2008
Venkat Gadachanda	09/03/2008
Cuixian Liu	09/03/2008
Jesse Quinn	09/20/2008
Shouming Li	09/03/2008
Dawei Chen	09/03/2008
Milind Deshpande	09/03/2008
Avinash Phadke	09/03/2008

RECEIVING PARTY DATA

Name:	Achillion Pharmaceuticals, Inc.
Street Address:	300 George Street
City:	New Haven
State/Country:	CONNECTICUT
Postal Code:	06511

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	12125554

CORRESPONDENCE DATA

Fax Number: (860)286-0115

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 860-286-2929

Email: jdesousa@cantorcolburn.com

Correspondent Name: CANTOR COLBURN, LLP

Address Line 1: 20 Church Street

Address Line 2: 22nd Floor

PATENT

500659040

REEL: 021592 FRAME: 0001

CH \$40.00 12125554

Address Line 4: Hartford, CONNECTICUT 06103

ATTORNEY DOCKET NUMBER:

API-0039

NAME OF SUBMITTER:

Leslie-Anne Maxwell

Total Attachments: 9

source=25E2248#page1.tif

source=25E2248#page2.tif

source=25E2248#page3.tif

source=25E2248#page4.tif

source=25E2248#page5.tif

source=25E2248#page6.tif

source=25E2248#page7.tif

source=25E2248#page8.tif

source=25E2248#page9.tif

ASSIGNMENT

WHEREAS We, **Xiangzhu Wang** of 4 Brushy Plain Road, Apt. #224, Branford, CT ; **Suoming Zhang** of 22 Dream Lake Drive, Madison CT ; **Venkat Gadhachanda** of 5121 Town Walk Drive, Hamden, CT; **Cuixian Liu** of 22 Blueberry Hill Drive, Madison, CT; **Jesse Quinn** of 60 Craigs Road, Windsor, CT; **Shouming Li** of 6 Brookfield Court, Cheshire, CT; **Dawei Chen** of 158 Saddle Hill Drive, Middletown, CT; **Milind Deshpande** of 44 Field Brook Road, Madison, CT; and **Avinash Phadke** of 51 Gilbert Lane, Branford, CT (hereinafter "ASSIGNORS") have invented certain new and useful improvements in:

HETEROARYL SUBSTITUTED THIAZOLES

for which we have filed application for Letters Patent of the United States on May 22, 2008, U.S. Patent Application No. 12/125,554; which claims priority from U.S. Provisional Patent Application No. 60/939,424 filed May 22, 2007;


AND WHEREAS, ACHILLION PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware, having a place of business at 300 George Street, New Haven, Connecticut 06511, is desirous of acquiring an interest in the United States and all foreign countries, in and to the said invention and Letters Patent to be obtained therefore;

NOW THEREFORE, TO ALL WHOM IT MAY CONCERN, be it known that, for good and sufficient consideration the, receipt of which is hereby acknowledged, We, the said ASSIGNORS; have sold, assigned, and transferred, and by these presents do sell, assign and transfer unto the said ACHILLION PHARMACEUTICALS, INC., the entire right, title and interest in and to said invention in the United States and in all foreign countries, including priority rights, as fully set forth and described in said application; and We do hereby authorize and request the Commissioner of Patents to issue said Letters Patent on said application, and any and all Letters Patent that may be issued upon any and all revivals, refilings, continuations, continuations-in-part, divisions and reissues thereof, to the said ACHILLION PHARMACEUTICALS, INC., an assignee of the entire right, title and interest in and to the same, for the sole use and behoof of ACHILLION PHARMACEUTICALS, INC., its successors and assigns; and We do hereby agree that the said ACHILLION PHARMACEUTICALS, INC., may apply for foreign Letters Patent on said invention and that We will execute all papers necessary in connection with the United States and foreign applications when called upon to do so by the said ACHILLION PHARMACEUTICALS, INC., its successors or assigns, and that We will, at the cost and expense of the said ACHILLION PHARMACEUTICALS, INC., fully

assist and cooperate in all matters in connection with the United States and foreign applications and patents issuing thereon.

The undersigned declare that all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 9/3/08


Xiangzhu Wang L.S.


Date: _____

Suoming Zhang L.S.

Date: 09/03/08


Venkat Gadhachanda L.S.

Date: 09/03/08


Cuixian Liu L.S.


Date: _____

Jesse Quinn L.S.

Date: 9/3/08



Shouming Li L.S.

Date: 9/3/08



Dawei Chen L.S.

API-0039

Date: 9/3/08

 L.S.
Milind Deshpande

Date: 9-3-08

 L.S.
Avinash Phadke

ASSIGNMENT

WHEREAS We, **Xiangzhu Wang** of 4 Brushy Plain Road, Apt. #224, Branford, CT ; **Suoming Zhang** of 22 Dream Lake Drive, Madison CT ; **Venkat Gadhachanda** of 5121 Town Walk Drive, Hamden, CT; **Cuixian Liu** of 22 Blueberry Hill Drive, Madison, CT; **Jesse Quinn** of 55 Alden Road, Windsor, CT; **Shouming Li** of 6 Brookfield Court, Cheshire, CT; **Dawei Chen** of 158 Saddle Hill Drive, Middletown, CT; **Milind Deshpande** of 44 Field Brook Road, Madison, CT; and **Avinash Phadke** of 51 Gilbert Lane, Branford, CT (hereinafter "ASSIGNORS") have invented certain new and useful improvements in:

HETEROARYL SUBSTITUTED THIAZOLES

for which we have filed application for Letters Patent of the United States on May 22, 2008, U.S. Patent Application No. 12/125,554; which claims priority from U.S. Provisional Patent Application No. 60/939,424 filed May 22, 2007;


AND WHEREAS, ACHILLION PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware, having a place of business at 300 George Street, New Haven, Connecticut 06511, is desirous of acquiring an interest in the United States and all foreign countries, in and to the said invention and Letters Patent to be obtained therefore;

NOW THEREFORE, TO ALL WHOM IT MAY CONCERN, be it known that, for good and sufficient consideration the, receipt of which is hereby acknowledged, We, the said ASSIGNORS; have sold, assigned, and transferred, and by these presents do sell, assign and transfer unto the said ACHILLION PHARMACEUTICALS, INC., the entire right, title and interest in and to said invention in the United States and in all foreign countries, including priority rights, as fully set forth and described in said application; and We do hereby authorize and request the Commissioner of Patents to issue said Letters Patent on said application, and any and all Letters Patent that may be issued upon any and all revivals, refilings, continuations, continuations-in-part, divisions and reissues thereof, to the said ACHILLION PHARMACEUTICALS, INC., an assignee of the entire right, title and interest in and to the same, for the sole use and behoof of ACHILLION PHARMACEUTICALS, INC., its successors and assigns; and We do hereby agree that the said ACHILLION PHARMACEUTICALS, INC., may apply for foreign Letters Patent on said invention and that We will execute all papers necessary in connection with the United States and foreign applications when called upon to do so by the said ACHILLION PHARMACEUTICALS, INC., its successors or assigns, and that We will, at the cost and expense of the said ACHILLION PHARMACEUTICALS, INC., fully

assist and cooperate in all matters in connection with the United States and foreign applications and patents issuing thereon.

The undersigned declare that all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: _____

Xiangzhu Wang L.S.Date: 9/24/08
Suoming Zhang L.S.

Date: _____

Venkat Gadhachanda L.S.

Date: _____

Cuixian Liu L.S.

Date: _____

Jesse Quinn L.S.

Date: _____

Shouming Li L.S.

Date: _____

Dawei Chen L.S.

API-0039

Date: _____

Milind Deshpande L.S.

Date: _____

Avinash Phadke L.S.

ASSIGNMENT

WHEREAS We, **Xiangzhu Wang** of 4 Brushy Plain Road, Apt. #224, Branford, CT ; **Suoming Zhang** of 22 Dream Lake Drive, Madison CT ; **Venkat Gadhachanda** of 5121 Town Walk Drive, Hamden, CT; **Cuixian Liu** of 22 Blueberry Hill Drive, Madison, CT; **Jesse Quinn** of 55 Alden Road, Windsor, CT; **Shouming Li** of 6 Brookfield Court, Cheshire, CT; **Dawei Chen** of 158 Saddle Hill Drive, Middletown, CT; **Milind Deshpande** of 44 Field Brook Road, Madison, CT; and **Avinash Phadke** of 51 Gilbert Lane, Branford, CT (hereinafter "ASSIGNORS") have invented certain new and useful improvements in:

HETEROARYL SUBSTITUTED THIAZOLES

for which we have filed application for Letters Patent of the United States on May 22, 2008, U.S. Patent Application No. 12/125,554; which claims priority from U.S. Provisional Patent Application No. 60/939,424 filed May 22, 2007;

AND WHEREAS, ACHILLION PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware, having a place of business at 300 George Street, New Haven, Connecticut 06511, is desirous of acquiring an interest in the United States and all foreign countries, in and to the said invention and Letters Patent to be obtained therefore;

NOW THEREFORE, TO ALL WHOM IT MAY CONCERN, be it known that, for good and sufficient consideration the, receipt of which is hereby acknowledged, We, the said ASSIGNORS; have sold, assigned, and transferred, and by these presents do sell, assign and transfer unto the said ACHILLION PHARMACEUTICALS, INC., the entire right, title and interest in and to said invention in the United States and in all foreign countries, including priority rights, as fully set forth and described in said application; and We do hereby authorize and request the Commissioner of Patents to issue said Letters Patent on said application, and any and all Letters Patent that may be issued upon any and all revivals, refilings, continuations, continuations-in-part, divisions and reissues thereof, to the said ACHILLION PHARMACEUTICALS, INC., an assignee of the entire right, title and interest in and to the same, for the sole use and behoof of ACHILLION PHARMACEUTICALS, INC., its successors and assigns; and We do hereby agree that the said ACHILLION PHARMACEUTICALS, INC., may apply for foreign Letters Patent on said invention and that We will execute all papers necessary in connection with the United States and foreign applications when called upon to do so by the said ACHILLION PHARMACEUTICALS, INC., its successors or assigns, and that We will, at the cost and expense of the said ACHILLION PHARMACEUTICALS, INC., fully

assist and cooperate in all matters in connection with the United States and foreign applications and patents issuing thereon.

The undersigned declare that all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: _____

_____. L.S.
Xiangzhu Wang

Date: _____

Suoming Zhang L.S.

Date: _____


L.S.

Venkat Gadachanda

Date: _____

_____ L.S.
Cuixian Liu

Date: 9/28/8

 L.S.
Jesse Quinn

Date: _____

Shouming Li L.S.

Date: _____

_____ L.S.
Dawei Chen

API-0039

Date: _____

Milind Deshpande L.S.

Date: _____

Avinash Phadke L.S.